HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) saw unusually-high trading volume on Monday . Approximately 71,022 shares traded hands during trading, an increase of 3% from the previous session's volume of 69,081 shares.The stock last traded at $16.03 and had previously closed at $14.99.
Wall Street Analysts Forecast Growth
Separately, StockNews.com lowered HUTCHMED from a "buy" rating to a "hold" rating in a research report on Monday, November 18th.
Get Our Latest Analysis on HUTCHMED
HUTCHMED Stock Performance
The stock's 50-day simple moving average is $16.59 and its 200 day simple moving average is $17.85. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.
Institutional Trading of HUTCHMED
Several institutional investors have recently added to or reduced their stakes in HCM. Rhumbline Advisers increased its stake in HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company's stock worth $129,000 after purchasing an additional 564 shares during the period. Vanguard Personalized Indexing Management LLC lifted its holdings in HUTCHMED by 9.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company's stock worth $226,000 after buying an additional 1,168 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in HUTCHMED in the 3rd quarter valued at approximately $35,000. China Universal Asset Management Co. Ltd. grew its stake in shares of HUTCHMED by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company's stock worth $117,000 after acquiring an additional 2,321 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of HUTCHMED by 638.2% during the third quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock worth $69,000 after acquiring an additional 3,057 shares during the period. Institutional investors and hedge funds own 8.82% of the company's stock.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
